NEW YORK & CHICAGO--(BUSINESS WIRE)-- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary Microdose Array Print ...
Today, we revisit a promising small ocular biopharma concern called Eyenovia for the first time in almost 18 months. The company continues to advance its pipeline and recently submitted a marketing ...
Please provide your email address to receive an email when new articles are posted on . Three years ago, tragedy struck my family with the loss of my brother due to metastatic lung cancer. My brother ...
NEW YORK--(BUSINESS WIRE)--Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company with Phase 3 programs in presbyopia, myopia and mydriasis, today announced that it has ...
Isolated anisocoria in the absence of ocular misalignment and ptosis raises suspicion for a tonic pupil. This diagnosis is further confirmed by the absence of other neurologic or systemic findings and ...
Mydriatic microdrops during retinopathy of prematurity (ROP) screening were noninferior to standard drops, which have been associated with cardiorespiratory and gastrointestinal adverse events, a ...
SHANGHAI, Sept. 16, 2021 /PRNewswire/ -- Arctic Vision, a China-based biotech company focused on innovative ophthalmic therapies, announced today that it will expand its exclusive license agreement ...
Cataract surgery remains one of the most frequently performed procedures worldwide, with continual improvements in techniques and tools yielding enhanced outcomes. Central to these advances is pupil ...
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback